Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem ...

Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Diltiazem Hydrochloride ...

Alembic Pharmaceuticals Limited received final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP. The approved strengths include 120 mg, 180 mg, and 240 mg.

360 mg: Light blue/white capsule imprinted with “cardizem CD 360 mg” on body. Supplied in a 90-count bottle. The therapeutic effects of diltiazem are believed to be related to its ability to ...

Refer label for a detailed indication. Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg have an estimated market size of US$ 28.2 million for twelve months ending ...